Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept

Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: An Observational Postauthorisation Study

The study will be an observational, cross-sectional study of knowledge, understanding, and self-reported behavior among a sample of physicians and patients with recent aflibercept experience in a total of up to five European countries.

Inclusion Criteria:

Physicians eligibility:

• Licensed and practicing ophthalmologist
• Prescribed and administered aflibercept to at least one patient in the past 6 months

Patients eligibility:

• Patient has been administered aflibercept at least once within the last 6 months for any indication and is returning for a subsequent visit.
• Patient is aged 18 years or older.
• Patient is able to understand and sign the consent form and patient questionnaire.
• Patient can understand the native language of the country in which the study is being conducted.
• Patient has not participated in a clinical trial for the treatment of an aflibercept indication (e.g., wAMD, CRVO, or DME) in the past 12 months.